01 / What it is
Tesamorelin is a stabilized 44-residue analog of growth-hormone-releasing hormone (GHRH). Rather than supplying growth hormone directly, it prompts the pituitary's own release in research models.
Research use onlySpecification publishedQualified users only
Endocrine & growth-factor research · AGX-06
Tesamorelin
The stabilized GHRH analog
$110
20 mg lyophilized vial$5.50/mg · research use only
Research use only · no human or veterinary use, consumption, administration, diagnosis, treatment, prevention, cosmetic use, or food use. Sold to qualified laboratory and analytical users.
02 / Mechanism in the literature
It binds the GHRH receptor on the pituitary, stimulating pulsatile growth-hormone secretion. Structural modifications improve its stability over native GHRH.
03 / Research context
Tesamorelin is studied in endocrine and body-composition literature, particularly in models of visceral-fat and GH-axis signaling.
Listed format20 mg lyophilized vial
Sequence44-residue GHRH analog
Molecular formulaC221H366N72O67S
Molecular weight5136 g/mol
Catalogue referenceAGX-06
Listed price$110
Size44 residues
TargetPituitary GHRH receptor
04 / Common questions
How is a secretagogue different from growth hormone?
A secretagogue prompts the body's own pituitary to release GH, rather than introducing GH directly.
Why is it stabilized?
Native GHRH degrades quickly; the analog's modifications extend its research half-life.